Form4insider filings, from the source

SEC Form 4 · accession 0001298711-26-000006

Krystal Biotech, Inc. · KRYS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Suma Krishnan
Officer — President, R&D · Director · 10% Owner
Period of report
Jun 4, 2026
Accepted (ET)
Jun 5, 2026 · 6:40 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001711279

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2Jun 4, 2026S320$300.75D1,402,835D
Common StockF3Jun 4, 2026S593$302.2508D1,402,242D
Common StockF4Jun 4, 2026S247$303.1703D1,401,995D
Common StockF5Jun 4, 2026S400$304.8939D1,401,595D
Common StockF6Jun 4, 2026S480$305.865D1,401,115D
Common StockF7Jun 4, 2026S1,348$307.0948D1,399,767D
Common StockF8Jun 4, 2026S12,729$307.8066D1,387,038D
Common StockF9Jun 4, 2026S3,803$308.8898D1,383,235D
Common StockF10Jun 4, 2026S2,801$309.9451D1,380,434D
Common StockF11Jun 4, 2026S2,039$310.937D1,378,395D
Common StockF12Jun 4, 2026S240$311.65D1,378,155D
Common StockF13holding———90,000IBy Krishnan Spousal Trust
Common StockF14holding———50,000IBy Krishnan Family Trust

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses